1-(苯磺酰基)-5-(溴甲基)吲哚 | 1184953-71-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(苯磺酰基)-5-(溴甲基)吲哚
• 中文别名: 1-苯磺酰基-5-(溴甲基)-1H-吲哚
• 英文名称: 5-(bromomethyl)-1-(phenylsulfonyl)-1H-indole
• 英文别名: 1-benzenesulfonyl-5-bromomethyl-1H-indole；1-(benzenesulfonyl)-5-(bromomethyl)indole
• CAS: 1184953-71-6
• 化学式: C₁₅H₁₂BrNO₂S
• 分子量: 350.236
• InChiKey: WEPKKLRCOPTNLP-UHFFFAOYSA-N

物化性质

• 沸点：
  516.1±42.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(苯磺酰基)-5-(溴甲基)吲哚 在 吗啉 、 盐酸 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 potassium peroxymonosulfate 、 sodium acetate 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 异丙醇 、 丙酮 为溶剂， 反应 37.25h， 生成 (3RS,4SR,5SR)-3-((3-(tert-butyl)benzyl)amino)-4-hydroxy-5-((1-(phenylsulfonyl)-1H-indol-5-yl)methyl)tetrahydro-2H-thiopyran 1,1-dioxide
  参考文献：
  名称：

  Discovery of Cyclic Sulfone Hydroxyethylamines as Potent and Selective β-Site APP-Cleaving Enzyme 1 (BACE1) Inhibitors: Structure-Based Design and in Vivo Reduction of Amyloid β-Peptides

  摘要：

  Structure-based design of a series of cyclic hydroxyethylamine BACE1 inhibitors allowed the rational incorporation of prime- and nonprime-side fragments to a central core template without any amide functionality. The core scaffold selection and the structure activity relationship development were supported by molecular modeling studies and by X-ray analysis of BACE1 complexes with various ligands to expedite the optimization of the series. The direct extension from P1-aryl- and heteroaryl moieties into the S3 binding pocket allowed the enhancement of potency and selectivity over cathepsin D. Restraining the design and synthesis of compounds to a physicochemical property space consistent with central nervous system drugs led to inhibitors with improved blood brain barrier permeability. Guided by structure-based optimization, we were able to obtain highly potent compounds such as 60p with enzymatic and cellular IC50 values of 2 and 50 nM, respectively, and with >200-fold selectivity over cathepsin D. Pharmacodynamic studies in APPS1/16 transgenic mice at oral doses of 180 mu mol/kg demonstrated significant reduction of brain A beta levels.

  DOI：

  10.1021/jm300069y
• 作为产物：
  描述：

  5-甲基-1-苯基磺酰基-1H-吲哚 在 2,2'-azobis(2-methylpropionitrile) 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 反应 5.0h， 以33%的产率得到1-(苯磺酰基)-5-(溴甲基)吲哚
  参考文献：
  名称：

  Substituted 4-aminocyclohexane derivatives

  摘要：

  具有以下式I的4-氨基环己烷衍生物，其中R1-R4如本文所述，其制备方法，含有这些化合物的药物产品和药物组合物，以及用于治疗疼痛的4-氨基环己烷衍生物的用途。

  公开号：

  US20090215725A1

文献信息

• Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment
  申请人：Bondy S. Steven

  公开号：US20070244148A1

  公开（公告）日：2007-10-18

  The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyridine prodrug having the general formula (Z): The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula and their use as a medicine or to treat or prevent viral infections.

  本发明涉及一种用于治疗或预防病毒感染的药物组合物，其包含至少一种具有以下通式（Z）的咪唑[4,5-c]吡啶前药作为活性成分：本发明还涉及制备符合上述通式的化合物的方法以及它们作为药物或用于治疗或预防病毒感染的用途。
• Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
  申请人：Puerstinger Gerhard

  公开号：US20090208456A1

  公开（公告）日：2009-08-20

  The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

  本发明涉及制备用于治疗或预防病毒感染的药物组合物，其中至少包括一种具有通式（A）的咪唑并[4,5-c]嘧啶类活性成分，其中取代基如规范所述。本发明还涉及制备符合上述通式的化合物的过程，其药学上可接受的配方以及它们作为药物或用于治疗或预防病毒感染的用途。
• SUBSTITUIERTE 4-AMINOCYCLOHEXAN-DERIVATE ZUR BEHANDLUNG VON SCHMERZ
  申请人：Grünenthal GmbH

  公开号：EP2254864B1

  公开（公告）日：2014-05-14
• US7648998B2
  申请人：——

  公开号：US7648998B2

  公开（公告）日：2010-01-19
• US7790730B2
  申请人：——

  公开号：US7790730B2

  公开（公告）日：2010-09-07